stockrowMedtronic PLC
MDT Healthcare Medical Devices
Medtronic PLC’s revenue for fiscal 2026 (year ended April 2026) was $36.4 billion, up 8.43% from fiscal 2025.
- Revenue
- +13.7%
- EPS
- +42.0%
- Free cash flow
- +120.9%
- Total debt
- −1.59%
Quarter to July 2026, against a year earlier
Follow MDT
Alert me
Medtronic PLC (MDT) EPS (diluted)
Medtronic PLC's EPS (diluted) for fiscal 2026 was $3.73, unchanged from fiscal 2025. Over the twelve months to 31 July 2026 it was $4.06. Over the past ten years it has ranged from $2.27 (fiscal 2018) to $3.73 (fiscal 2026) — the current reading is the highest in ten years. Medtronic PLC ranks 9th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | $3.73 | 3.32% |
| FY2025 | $3.61 | 30.80% |
| FY2024 | $2.76 | (2.13%) |
| FY2023 | $2.82 | (24.40%) |
| FY2022 | $3.73 | 40.23% |
| FY2021 | $2.66 | (24.86%) |
| FY2020 | $3.54 | 3.81% |
| FY2019 | $3.41 | 50.22% |
| FY2018 | $2.27 | (21.45%) |
| FY2017 | $2.89 | 16.53% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jul 2026 | $1.14 | 18.75% |
| Apr 2026 | $0.96 | 7.87% |
| Jan 2026 | $0.89 | (16.82%) |
| Oct 2025 | $1.07 | 32.10% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| SYK Stryker Corporation compare | $9.39 |
| STE STERIS plc compare | $8.43 |
| GEHC GE HealthCare Technologies Inc. compare | $4.76 |
| MDT Medtronic PLC | $4.06 |
| ABT Abbott Laboratories compare | $2.68 |
| DXCM DexCom, Inc. compare | $2.55 |
| BSX Boston Scientific Corporation compare | $2.36 |
| EW Edwards Lifesciences Corporation compare | $1.77 |
| PHG Koninklijke Philips N.V. compare | $1.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on MDT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement